Navigation Links
J.D. Power and Associates Reports: Riverview Medical Center Recognized for Providing an Emergency Department Experience
Date:2/27/2008

WESTLAKE VILLAGE, Calif., Feb. 27 /PRNewswire/ -- Riverview Medical Center, located in Red Bank, N.J., has been recognized for service excellence under the J.D. Power and Associates Distinguished Hospital Program(SM). This distinction acknowledges a strong commitment by Riverview Medical Center to provide an "outstanding emergency department experience."

(Logo: http://www.newscom.com/cgi-bin/prnh/20050527/LAF028LOGO-a)

The service excellence distinction was determined by surveying recently discharged patients from Riverview on their perceptions of their emergency room visit and comparing the results to the national benchmark established by the annual J.D. Power and Associates National Hospital Service Performance Study(SM).

The telephone-based research conducted among Riverview patients focuses on the five key drivers of patient satisfaction with their overall hospital experience. These drivers, which were identified in the national study, include: speed and efficiency; dignity and respect; comfort; information and communication; and emotional support.

"Based on the rigorous standards of our national hospital service performance research, only 20 percent of the hospitals in the nation will be qualified to achieve this distinction," said David Stefan, executive director of the healthcare division of J.D. Power and Associates. "Riverview Medical Center is among an elite class of hospitals."

Riverview Medical Center exceeded the national emergency department benchmark study score for patient satisfaction by a notable margin. In comparison to the national study, the Riverview Medical Center's emergency department performed well on providing patients with a comfortable experience, particularly with their concern for comfort during the blood drawing procedures. They also scored well with the nurses' concern about controlling pain, an important as
'/>"/>

SOURCE J.D. Power and Associates
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Northwestern Memorial Hospitals Steven J. Stryker MD Unveils Campaign With Empower Public Relations
2. Venture Global Limited Introduces an Innovative Anti-Cellphone Radiation Sticker Named VEGO Power Blocker
3. Dr. Carolyn Jacob Hires Empower Public Relations
4. Cleveland Clinic Press Consumer Health Book Empowers and Gives Hope to People with Epilepsy
5. Providence Health & Services - Oregon Region Powers Consumer Portal With Kryptiq Connect IQ
6. An Event Added to Celebrate and Empower North Carolina Women
7. Flextronics to Acquire the FRIWO Mobile Power Business Unit of CEAG
8. Healing Our Land, Inc. and The Massachusetts Black Legislative Caucus Convene Prevention Is Power Community Forum on the Impact of HIV/AIDS on Communities of Color in Massachusetts
9. J.D. Power and Associates Reports: The Nebraska Medical Center Recognized for Providing an Outstanding Inpatient Experience for a Third Consecutive Year, and for Providing an Outstanding Cardiovascular Experience
10. The SCOOTER Store Donates Power Wheelchair to New Braunfels Car Crash Victim
11. Integrated Laser Therapies Launches, Offers Low-power, Therapeutic Laser Devices and Training for Therapists and Consumers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/5/2008)...tic children whose parents have high expectations ...kely to have symptoms than other children dealing ...dren also are more likely to use asthma controller...for taking medicine and if their parents clearly u... The study, which appears in the Oct. 2008 issue o...
(Date:10/3/2008)...ding is beneficial. But can it help kids lose weig...terature on obese adolescents, researchers at Duke...ight type of novel may make a difference. , The ...who were already in a comprehensive weight loss pr... Rescue (Beacon Street Press). It was carefully cr...
(Date:10/3/2008)... Inc. Magazine recently included,Connolly Consulti...ng,private companies in the country. The list is t...egment of the economy -- America,s,independent-min...es,represent the backbone of the U.S. economy., (...3/NY36880LOGO ), Connolly Consulting,s consisten...
(Date:10/3/2008)...idents to Eat Right, Move More and ...t. 3 /PRNewswire/ -- The last decade can be define...hich seem to go in and out,of fashion like shoulde...en,slim. Two out of three Americans -- including 2...weight or obese., A new campaign crossing the cou...
Breaking Medicine News(10 mins):Health News:Children's asthma affected by parental expectations 2Health News:Duke researchers show reading can help obese kids lose weight 2Health News:Connolly Consulting Makes the 2008 Inc. Magazine's List of America's 5000 Fastest Growing Companies 2Health News:Message to Pennsylvania Residents: Forgo Fad Dieting and Join the Campaign for Healthy Weight 2Health News:Message to Pennsylvania Residents: Forgo Fad Dieting and Join the Campaign for Healthy Weight 3
...unction is associated with loss of libido, low mot... who have attained their menopause or whose ovarie...ydroepiandosterone(DHEA), may serve as an effectiv...according to a study released at the 96th annual m...
...h Israel Deaconess Medical Center reported in the ...perimental Gene Therapy method has safely introduc...a. This method shows signs of helping these men f... protein they lack. None of the patients suffers ...
...ip seems to be the latest mantra of Pfizer. The p...ply free antifungal drug to 50 countries hardest h...omes close on the heels of the South African Gover...cal companies. In an announcement on Wednesday Pf...
...napat Rao Matapurkar, from Maulana Azad Medical Co...inning the first patent on organ regeneration from...uccessfully regenerating / repairing organs in hum... patent office granted him a patent on this techni...
Other Medicine News:
(Date:10/6/2008)...se 3b Studies with Durezol Dosed Prior to Surgery,...peutics, Inc., a,privately held ophthalmic-focused...urezol(TM) (difluprednate ophthalmic emulsion) 0.0...as approved by the U.S. Food and,Drug Administrati...eroid,indicated for the treatment of inflammation ...
(Date:10/6/2008)...lif. and SEATTLE, Oct. 6 /- Complete,...human genome sequencing,company, and the Institute...artnership to conduct populationwide human genome ...enomics will use its proprietary,DNA sequencing te...vided by,ISB. Then, once proof-of-concept has been...
(Date:10/6/2008)...netic Characteristics of Naltrexone SR Associated ...l Trials -, PHOENIX, Oct. 6 /PRNewswire-FirstCall... a biopharmaceutical company focused on the treatm...lated disorders, today presented,data showing the ...,bupropion SR), successfully achieved key objectiv...
(Date:10/6/2008)...Other Product - Company,s Bioabsorbable Stent - Al...G, Oct. 6 /- Data from multiple clini... OrbusNeich,s Genous Bio-engineered R,stent, will ...vascular,Therapeutics symposium, TCT 2008, in Wash...the Academic Medical Center in,Amsterdam will prov...
Breaking Medicine Technology:Video: Sirion Therapeutics Launches Durezol for Postoperative Ocular Inflammation and Pain 2Video: Sirion Therapeutics Launches Durezol for Postoperative Ocular Inflammation and Pain 3Video: Sirion Therapeutics Launches Durezol for Postoperative Ocular Inflammation and Pain 4Video: Sirion Therapeutics Launches Durezol for Postoperative Ocular Inflammation and Pain 5Complete Genomics and the Institute for Systems Biology Announce Partnership to Conduct the First Human Genome Population Study 2Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R) 2Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R) 3Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R) 4Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R) 5Data From Multiple Clinical Trials of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) to be Presented at TCT 2008 2Data From Multiple Clinical Trials of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) to be Presented at TCT 2008 3Shire Strives to Increase Adherence Among Chronic Kidney Disease Stage 5 Patients 1685 1Shire Strives to Increase Adherence Among Chronic Kidney Disease Stage 5 Patients 1685 2Shire Strives to Increase Adherence Among Chronic Kidney Disease Stage 5 Patients 1685 3Shire Strives to Increase Adherence Among Chronic Kidney Disease Stage 5 Patients 1685 4Shire Strives to Increase Adherence Among Chronic Kidney Disease Stage 5 Patients 1685 5Shire Strives to Increase Adherence Among Chronic Kidney Disease Stage 5 Patients 1685 6Shire Strives to Increase Adherence Among Chronic Kidney Disease Stage 5 Patients 1685 7Shire Strives to Increase Adherence Among Chronic Kidney Disease Stage 5 Patients 1685 8Essential nutrient found in eggs reduces risk of breast cancer by 24 percent 15878 1Essential nutrient found in eggs reduces risk of breast cancer by 24 percent 15878 2Essential nutrient found in eggs reduces risk of breast cancer by 24 percent 15878 3Veterinary college researchers explore function of biofilm in bovine respiratory disease 2738 1Veterinary college researchers explore function of biofilm in bovine respiratory disease 2738 2Food for thought 2735 2/ 1
... Jun 09, 2007 (MARKET WIRE via COMTEX News Network...sidiary of Endo,Pharmaceuticals Holdings Inc. (NAS... randomized, double-blind, placebo-controlled,clin...e) 2.5 mg,tablets as a six-day preventative treatm...raine (MM). The data demonstrated,that FROVA signi...
...., June 11, 2007--New research supported by the,...of Arthritis and,Musculoskeletal and Skin Diseas...ion gabapentin , which is used for certain,type...he pain and,other symptoms associated with the c..., fibromyalgia. , In the NIAMS-sponsored, random...
Other Medicine Technology:Frova Phase III Study Data Demonstrates That Short-Term Prevention,Treatment Reduces Frequency and Severity of Menstrual Migraine 2Frova Phase III Study Data Demonstrates That Short-Term Prevention,Treatment Reduces Frequency and Severity of Menstrual Migraine 3Frova Phase III Study Data Demonstrates That Short-Term Prevention,Treatment Reduces Frequency and Severity of Menstrual Migraine 4Frova Phase III Study Data Demonstrates That Short-Term Prevention,Treatment Reduces Frequency and Severity of Menstrual Migraine 5Frova Phase III Study Data Demonstrates That Short-Term Prevention,Treatment Reduces Frequency and Severity of Menstrual Migraine 6Frova Phase III Study Data Demonstrates That Short-Term Prevention,Treatment Reduces Frequency and Severity of Menstrual Migraine 7Gabapentin Shown Effective for Fibromyalgia Pain 2Gabapentin Shown Effective for Fibromyalgia Pain 3
BiodivYsio stent with biocompatible coating (phosphorylcholine)
The CYPHER Sirolimus-eluting Coronary Stent consists of a proven antiproliferative drug, called "sirolimus", a controlled-release polymer, and a closed-cell stent delivery platform. Upon placement, s
PT wires combine the enhanced durability of a linear elastic nitinol distal core and a highly resilient polymer tip. This provides excellent access in difficult cases involving severe tortuosity, tig
Forte Guide Wire w/Markers: Front line use, 1:1 torque, excellent steering and tracking, sharp vessel images, floppy and moderate support.
Medicine Products: